This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

This study has been completed.
Information provided by (Responsible Party):
Corcept Therapeutics Identifier:
First received: June 7, 2011
Last updated: February 19, 2014
Last verified: February 2014
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.

Condition Intervention Phase
Cushing's Disease Cushing's Syndrome Drug: Mifepristone Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Resource links provided by NLM:

Further study details as provided by Corcept Therapeutics:

Primary Outcome Measures:
  • Number of Participants With Adverse Events [ Time Frame: 6 months ]
    Safety was assessed at all visits and adverse events were recorded.

Enrollment: 4
Study Start Date: November 2010
Study Completion Date: September 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mifepristone Drug: Mifepristone
mifepristone at doses from 300mg/day up to 1200mg/day
Other Name: CORLUX®


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Have a confirmed diagnosis of endogenous hypercortisolemia caused by ACTH dependent or ACTH independent etiologies including:

    • Cushing's Disease that (more than one may apply)

      • has recurred after primary pituitary surgery
      • has persisted despite pituitary surgery (failed pituitary surgery)
      • has been treated with radiation therapy to the pituitary
      • is not treatable with surgery
      • exists in subjects who are not candidates for or who refuse surgery
    • Ectopic ACTH
    • Ectopic CRF secretion
    • Adrenal adenoma
    • Adrenal carcinoma
    • Adrenal autonomy
  2. Have documented biochemical evidence of endogenous hypercortisolemia which includes elevated urinary free cortisol.
  3. Require medical treatment of hypercortisolemia.

Exclusion Criteria:

Individuals not eligible to be enrolled into the study are those who:

  • Have de novo Cushing's disease and are surgical candidates for pituitary surgery.
  • Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment.
  • Taking medications within 14 days of the baseline visit (Day 1) that a) have a large first pass metabolism largely mediated by CYP3A4 and a narrow therapeutic margin and/or b) are strong CYP3A4 inhibitors.
  • Female patients of reproductive potential, who are pregnant or who are unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study.
  • Have received investigational treatment (drug, biological agent or device) within 30 days of Screening
  • Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)
  • Have a non-endogenous source of hypercortisolemia such as factious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing's syndrome), factious or therapeutic use of ACTH
  • Have Pseudo-Cushing's syndrome.
  • Postmenopausal women with an intact uterus who have experienced unexplained vaginal bleeding within 12 months of Screening are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01371565

United States, Florida
The Center for Diabetes and Endocrine Care
Hollywood, Florida, United States, 33021
United States, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 48109
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
The Ohio State University, Division of Endocrinology Diabetes and Metabolism
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Corcept Therapeutics
Study Director: Coleman Gross, M.D. Corcept Therapeutics
  More Information

Responsible Party: Corcept Therapeutics Identifier: NCT01371565     History of Changes
Other Study ID Numbers: C1073-405
Study First Received: June 7, 2011
Results First Received: September 19, 2013
Last Updated: February 19, 2014

Keywords provided by Corcept Therapeutics:
Cushing's Disease
Cushing's Syndrome
Ectopic ACTH secretion

Additional relevant MeSH terms:
Cushing Syndrome
Signs and Symptoms
Pituitary ACTH Hypersecretion
ACTH-Secreting Pituitary Adenoma
Pathologic Processes
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral processed this record on September 21, 2017